433 related articles for article (PubMed ID: 32820478)
1. Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.
Hashemi A; Madhavan MV; Bikdeli B
Semin Thromb Hemost; 2020 Oct; 46(7):789-795. PubMed ID: 32820478
[No Abstract] [Full Text] [Related]
2. Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19.
Horowitz NA; Brenner B
Semin Thromb Hemost; 2020 Oct; 46(7):785-788. PubMed ID: 32785920
[No Abstract] [Full Text] [Related]
3. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism.
Schulman S
Semin Thromb Hemost; 2020 Oct; 46(7):772-776. PubMed ID: 32392613
[No Abstract] [Full Text] [Related]
5. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
Ahmed S; Zimba O; Gasparyan AY
Clin Rheumatol; 2020 Sep; 39(9):2529-2543. PubMed ID: 32654082
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
Thromb Haemost; 2020 Jul; 120(7):1004-1024. PubMed ID: 32473596
[TBL] [Abstract][Full Text] [Related]
7. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
8. Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020.
Ramacciotti E; Macedo AS; Biagioni RB; Caffaro RA; Lopes RD; Guerra JC; Orsi FA; Marques MA; Tafur AJ; Caprini JA; Nicolaides A; Carter CA; Filho CC; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936350. PubMed ID: 32649232
[TBL] [Abstract][Full Text] [Related]
9. Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?
Piazza O
Infez Med; 2020 Jun; 28(suppl 1):4-5. PubMed ID: 32532932
[TBL] [Abstract][Full Text] [Related]
10. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
Spyropoulos AC; Levy JH; Ageno W; Connors JM; Hunt BJ; Iba T; Levi M; Samama CM; Thachil J; Giannis D; Douketis JD;
J Thromb Haemost; 2020 Aug; 18(8):1859-1865. PubMed ID: 32459046
[No Abstract] [Full Text] [Related]
11. COVID-19 coagulopathy: an evolving story.
The Lancet Haematology
Lancet Haematol; 2020 Jun; 7(6):e425. PubMed ID: 32470428
[No Abstract] [Full Text] [Related]
12. Venous thromboembolism in non-critically ill patients with COVID-19 infection.
Trimaille A; Curtiaud A; Marchandot B; Matsushita K; Sato C; Leonard-Lorant I; Sattler L; Grunebaum L; Ohana M; Von Hunolstein JJ; Andres E; Goichot B; Danion F; Kaeuffer C; Poindron V; Ohlmann P; Jesel L; Morel O
Thromb Res; 2020 Sep; 193():166-169. PubMed ID: 32707275
[TBL] [Abstract][Full Text] [Related]
13. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
Miesbach W; Makris M
Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
[TBL] [Abstract][Full Text] [Related]
14. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?
Thachil J; Srivastava A
Semin Thromb Hemost; 2020 Oct; 46(7):777-780. PubMed ID: 32396963
[No Abstract] [Full Text] [Related]
15. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.
Capoluongo E
Biomed Pharmacother; 2020 Oct; 130():110536. PubMed ID: 32688139
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
Marietta M; Ageno W; Artoni A; De Candia E; Gresele P; Marchetti M; Marcucci R; Tripodi A
Blood Transfus; 2020 May; 18(3):167-169. PubMed ID: 32281926
[No Abstract] [Full Text] [Related]
17. Venous thromboembolism and COVID-19.
Bertoletti L; Couturaud F; Montani D; Parent F; Sanchez O
Respir Med Res; 2020 Nov; 78():100759. PubMed ID: 32474397
[No Abstract] [Full Text] [Related]
18. Long lasting hypercoagulability after subclinical COVID-19.
Ferroli P; Villa C; Ciuffi A; Gubertini G; Broggi M
J Thromb Thrombolysis; 2020 Nov; 50(4):822-824. PubMed ID: 32757154
[No Abstract] [Full Text] [Related]
19. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.
Godoy LC; Goligher EC; Lawler PR; Slutsky AS; Zarychanski R
CMAJ; 2020 Oct; 192(40):E1156-E1161. PubMed ID: 32816822
[No Abstract] [Full Text] [Related]
20. The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection.
Di Perri G
Infez Med; 2020 Jun; 28(suppl 1):52-56. PubMed ID: 32532939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
